Ignite Creation Date:
2025-12-25 @ 4:08 AM
Ignite Modification Date:
2025-12-26 @ 3:05 AM
Study NCT ID:
NCT06079320
Status:
TERMINATED
Last Update Posted:
2025-11-10
First Post:
2023-10-06
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Argentina', 'Australia', 'Canada', 'South Africa', 'Taiwan'], 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2025-08-17', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D018357', 'term': 'Respiratory Syncytial Virus Infections'}], 'ancestors': [{'id': 'D018186', 'term': 'Pneumovirus Infections'}, {'id': 'D018184', 'term': 'Paramyxoviridae Infections'}, {'id': 'D018701', 'term': 'Mononegavirales Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D007239', 'term': 'Infections'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000717948', 'term': 'sisunatovir'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrials.gov_Inquiries@pfizer.com', 'phone': '18007181021', 'title': 'Pfizer ClinicalTrials.gov Call Center', 'organization': 'Pfizer Inc.'}, 'certainAgreement': {'otherDetails': 'Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}, 'limitationsAndCaveats': {'description': 'A limitation of these results was the early study termination. Due to the small sample size, the study was no longer powered to establish the efficacy for the primary and key secondary efficacy endpoints for sisunatovir compared to placebo.'}}, 'adverseEventsModule': {'timeFrame': 'From Day 1 of study intervention up to 28-30 days after last dose of study drug (up to Day 35)', 'description': 'SAS included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention.', 'eventGroups': [{'id': 'EG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.', 'otherNumAtRisk': 8, 'deathsNumAtRisk': 8, 'otherNumAffected': 1, 'seriousNumAtRisk': 8, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Placebo', 'description': 'Participants received oral doses of placebo from Day 1 to Day 5.', 'otherNumAtRisk': 8, 'deathsNumAtRisk': 8, 'otherNumAffected': 4, 'seriousNumAtRisk': 8, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v27.1'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v27.1'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v27.1'}, {'term': 'Gamma-glutamyltransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v27.1'}, {'term': 'Head discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v27.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 8, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v27.1'}], 'frequencyThreshold': '1'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Number of Participants With Respiratory Syncytial Virus (RSV) Related Hospitalization or Death From Any Cause Through Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received oral doses of placebo from Day 1 to Day 5.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From Day 1 (start of study intervention) up to Day 28', 'description': 'RSV related hospitalization included a specialized acute medical care unit within an assisted living facility or nursing home.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Modified Intent-to-Treat-Infected (mITT-infected) population included all participants randomly assigned to study intervention, who took at least 1 dose of study intervention, and who had confirmed RSV infection.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With RSV-Related Visits (Urgent Care/ Emergency Department (ED)/Hospital) or Death From Any Cause Through Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received oral doses of placebo from Day 1 to Day 5.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From Day 1 (start of study intervention) up to Day 28', 'description': 'Participants with RSV related visits in a hospital/urgent care or ED requiring no minimum duration of hospitalization were reported in this outcome measure. Investigators determined if a medical visit was related to RSV. RSV-related medical visits were those attendances that would not otherwise occur in the absence of the RSV infection. These may have included: deterioration or decompensation of the lung function that required supplemental oxygen; development of secondary respiratory tract infections that required antibiotic treatment; management of severe symptoms associated with RSV such as fever; worsening or decompensation of cardiac or renal function in participants with underlying cardiac or renal disease.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT-infected population included all participants randomly assigned to study intervention, who took at least 1 dose of study intervention, and who had confirmed RSV infection.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Progression of Lower Respiratory Tract Infection (LRTI) Through Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received oral doses of placebo from Day 1 to Day 5.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From randomization on Day 1 up to Day 10', 'description': 'Progression of LRTI was defined as development of LRTI or transition from non-severe LRTI-RSV at randomization to severe LRTI-RSV at any time up to and including Day 10. LRTI was defined as: \\>= 2 lower respiratory signs or symptoms for at least 24 hours including at least 1 lower respiratory sign; or 3 lower respiratory symptoms for at least 24 hours. Lower respiratory symptoms included following: new or increased sputum, new or increased cough, new or increased dyspnea (shortness of breath). Lower respiratory signs included: new or increased wheezing, new or increased crackles/ronchi based on chest auscultation, respiratory rate \\>= 20 respirations/minute, low or decreased oxygen saturation (O2 less than (\\<) 95 percent (%) or \\<= 90% if pre-season baseline is \\< 95%), need for new or increased oxygen supplementation.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT-infected population included all participants randomly assigned to study intervention, who took at least 1 dose of study intervention, and who had confirmed RSV infection. Here "Overall Number of Participants Analyzed" signifies the number of participants evaluable for this outcome measure.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Development of LRTI Through Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received oral doses of placebo from Day 1 to Day 5.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From randomization on Day 1 up to Day 10', 'description': 'Development of LRTI was defined as transitioning from not having LRTI at randomization but having nsLRTI-RSV or sLRTI-RSV at any time up to and including Day 10. LRTI was defined as: \\>= 2 lower respiratory signs or symptoms for at least 24 hours including at least 1 lower respiratory sign; or 3 lower respiratory symptoms for at least 24 hours. Lower respiratory symptoms included following: new or increased sputum, new or increased cough, new or increased dyspnea (shortness of breath). Lower respiratory signs included: new or increased wheezing, new or increased crackles/ronchi based on chest auscultation, respiratory rate \\>= 20 respirations/minute, low or decreased oxygen saturation (O2 \\< 95 % or \\<= 90% if pre-season baseline is \\< 95%), need for new or increased oxygen supplementation.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT-infected population included all participants randomly assigned to study intervention, who took at least 1 dose of study intervention, and who had confirmed RSV infection. Here "Overall Number of Participants Analyzed" signifies the number of participants evaluable for this outcome measure.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Resolution of LRTI at Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received oral doses of placebo from Day 1 to Day 5.'}], 'classes': [{'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 15', 'description': 'Resolution of LRTI was defined as transition from RSV-related non-severe LRTI (nsLRTI-RSV) or RSV-related severe LRTI (sLRTI-RSV) at randomization to not having nsLRTI and sLRTI-RSV. LRTI was defined as: \\>= 2 lower respiratory signs or symptoms for at least 24 hours including at least 1 lower respiratory sign; or 3 lower respiratory symptoms for at least 24 hours. Lower respiratory symptoms included following: new or increased sputum, new or increased cough, new or increased dyspnea (shortness of breath). Lower respiratory signs included: new or increased wheezing, new or increased crackles/ronchi based on chest auscultation, respiratory rate \\>= 20 respirations/minute, low or decreased oxygen saturation (O2 \\< 95 % or \\<= 90% if pre-season baseline is \\< 95%), need for new or increased oxygen supplementation.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT-infected population included all participants randomly assigned to study intervention, who took at least 1 dose of study intervention, and who had confirmed RSV infection. Here "Overall Number of Participants Analyzed" signifies the number of participants evaluable for this outcome measure.'}, {'type': 'SECONDARY', 'title': 'Mean Number of Hospital Free Days Through Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received oral doses of placebo from Day 1 to Day 5.'}], 'classes': [{'categories': [{'measurements': [{'value': '28.0', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '28.0', 'spread': '0.00', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'From Day 1 (start of study intervention) up to Day 28', 'unitOfMeasure': 'Days', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT-infected population included all participants randomly assigned to study intervention, who took at least 1 dose of study intervention, and who had confirmed RSV infection.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Progression of LRTI Through Days 3, 5, 15 and 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received oral doses of placebo from Day 1 to Day 5.'}], 'classes': [{'title': 'Day 3', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Day 15', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Day 28', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From randomization on Day 1 up to Days 3, 5, 15 and 28', 'description': 'Progression of LRTI was defined as development of LRTI or transition from non severe LRTI-RSV at randomization to severe LRTI-RSV at any time up to and including Days 3, 5, 15 and 28. LRTI was defined as: \\>= 2 lower respiratory signs or symptoms for at least 24 hours including at least 1 lower respiratory sign; or 3 lower respiratory symptoms for at least 24 hours. Lower respiratory symptoms included following: new or increased sputum, new or increased cough, new or increased dyspnea (shortness of breath). Lower respiratory signs included: new or increased wheezing, new or increased crackles/ronchi based on chest auscultation, respiratory rate \\>= 20 respirations/minute, low or decreased oxygen saturation (O2 \\< 95 % or \\<= 90% if pre-season baseline is \\< 95%), need for new or increased oxygen supplementation.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT-infected population included all participants randomly assigned to study intervention, who took at least 1 dose of study intervention, and who had confirmed RSV infection. Here "Overall Number of Participants Analyzed" signifies the number of participants evaluable for this outcome measure.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Development of LRTI Through Days 3, 5, 15 and 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received oral doses of placebo from Day 1 to Day 5.'}], 'classes': [{'title': 'Day 3', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Day 15', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Day 28', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From randomization on Day 1 up to Days 3, 5, 15 and 28', 'description': 'Development of LRTI was defined as transitioning from not having LRTI at randomization but having nsLRTI-RSV or sLRTI-RSV at any time up to and including Days 3, 5, 15 and 28. LRTI was defined as: \\>= 2 lower respiratory signs or symptoms for at least 24 hours including at least 1 lower respiratory sign; or 3 lower respiratory symptoms for at least 24 hours. Lower respiratory symptoms included following: new or increased sputum, new or increased cough, new or increased dyspnea (shortness of breath). Lower respiratory signs included: new or increased wheezing, new or increased crackles/ronchi based on chest auscultation, respiratory rate \\>= 20 respirations/minute, low or decreased oxygen saturation (O2 \\< 95 % or \\<= 90% if pre-season baseline is \\< 95%), need for new or increased oxygen supplementation.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT-infected population included all participants randomly assigned to study intervention, who took at least 1 dose of study intervention, and who had confirmed RSV infection. Here "Overall Number of Participants Analyzed" signifies the number of participants evaluable for this outcome measure.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Resolution of LRTI at Days 3, 5, 10 and 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received oral doses of placebo from Day 1 to Day 5.'}], 'classes': [{'title': 'Day 3', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Day 10', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Day 28', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'At Days 3, 5, 10 and 28', 'description': 'Resolution of LRTI was defined as transition from nsLRTI-RSV or sLRTI-RSV at randomization to not having nsLRTI and sLRTI-RSV. LRTI was defined as \\>= 2 lower respiratory signs or symptoms for at least 24 hours including at least 1 lower respiratory sign; or 3 lower respiratory symptoms for at least 24 hours. Lower respiratory symptoms included following: new or increased sputum, new or increased cough, new or increased dyspnea (shortness of breath). Lower respiratory signs included: new or increased wheezing, new or increased crackles/ronchi based on chest auscultation, respiratory rate \\>= 20 respirations/minute, low or decreased oxygen saturation (O2 \\< 95% or \\<= 90% if pre-season baseline is \\< 95%), need for new or increased oxygen supplementation.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT-infected population included all participants randomly assigned to study intervention, who took at least 1 dose of study intervention, and who had confirmed RSV infection. Here, "Overall Number of Participants Analyzed" signifies the number of participants evaluable for this outcome measure.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Improvement of LRTI at Days 3, 5, 10, 15 and 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received oral doses of placebo from Day 1 to Day 5.'}], 'classes': [{'title': 'Day 3', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}]}]}, {'title': 'Day 10', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}]}]}, {'title': 'Day 15', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}]}]}, {'title': 'Day 28', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'At Days 3, 5, 10, 15 and 28', 'description': 'Improvement in LRTI status was defined as LRTI resolution or transition from sLRTI-RSV at randomization to nsLRTI-RSV. LRTI was defined as: \\>= 2 lower respiratory signs or symptoms for at least 24 hours including at least 1 lower respiratory sign; or 3 lower respiratory symptoms for at least 24 hours. Lower respiratory symptoms included following: new or increased sputum, new or increased cough, new or increased dyspnea (shortness of breath). Lower respiratory signs included: new or increased wheezing, new or increased crackles/ronchi based on chest auscultation, respiratory rate \\>= 20 respirations/minute, low or decreased oxygen saturation (O2 \\< 95 % or \\<= 90% if pre-season baseline is \\< 95%), need for new or increased oxygen supplementation.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT-infected population included all participants randomly assigned to study intervention, who took at least 1 dose of study intervention, and who had confirmed RSV infection. Here "Overall Number of Participants Analyzed" signifies the number of participants evaluable for this outcome measure.'}, {'type': 'SECONDARY', 'title': 'Mean Number of RSV Related Days in Hospital Through Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received oral doses of placebo from Day 1 to Day 5.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'spread': '0', 'groupId': 'OG000'}, {'value': '0', 'spread': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'From Day 1 (start of study intervention) up to Day 28', 'description': 'RSV related hospitalization included a specialized acute medical care unit within an assisted living facility or nursing home.', 'unitOfMeasure': 'Days', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT-infected population included all participants randomly assigned to study intervention, who took at least 1 dose of study intervention, and who had confirmed RSV infection.'}, {'type': 'SECONDARY', 'title': 'Mean Number of RSV Related Days in Intensive Care Unit (ICU) Through Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received oral doses of placebo from Day 1 to Day 5.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'spread': '0', 'groupId': 'OG000'}, {'value': '0', 'spread': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'From Day 1 (start of study intervention) up to Day 28', 'unitOfMeasure': 'Days', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT-infected population included all participants randomly assigned to study intervention, who took at least 1 dose of study intervention, and who had confirmed RSV infection.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With a Clinical Response of Improvement or Resolution at Days 5, 10, 15, and 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received oral doses of placebo from Day 1 to Day 5.'}], 'classes': [{'title': 'Day 5', 'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}]}, {'title': 'Day 10', 'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}]}, {'title': 'Day 15', 'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}]}, {'title': 'Day 28', 'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'At Days 5, 10, 15, and 28', 'description': 'Improvement was defined as no new acute respiratory infection (ARI) signs or symptoms, and no worsening of existing signs or symptoms compared to the Day 1 visit. At least one sign or symptom (but not all) present at Day 1 was absent, improved or returned to pre-infection status. Resolution was defined as all ARI signs or symptoms were absent or returned to pre-infection status. Clinical response was evaluated by the investigator.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT-infected population included all participants randomly assigned to study intervention, who took at least 1 dose of study intervention, and who had confirmed RSV infection.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Undetectable RSV Viral Load at Days 3, 5, 10, 15 and 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received oral doses of placebo from Day 1 to Day 5.'}], 'classes': [{'title': 'Day 3', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Day 10', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}]}]}, {'title': 'Day 15', 'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}]}, {'title': 'Day 28', 'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'At Days 3, 5, 10, 15, and 28', 'description': 'Undetectable RSV viral load at a visit was defined as a central PCR laboratory result of target not detected (TND).', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT-infected population included all participants randomly assigned to study intervention, who took at least 1 dose of study intervention, and who had confirmed RSV infection.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Log10 Transformed Total RSV Viral Load at Days 3, 5, 10, 15 and 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received oral doses of placebo from Day 1 to Day 5.'}], 'classes': [{'title': 'Day 3', 'categories': [{'measurements': [{'value': '-1.453', 'spread': '1.2107', 'groupId': 'OG000'}, {'value': '-1.184', 'spread': '1.2960', 'groupId': 'OG001'}]}]}, {'title': 'Day 5', 'categories': [{'measurements': [{'value': '-1.788', 'spread': '2.0327', 'groupId': 'OG000'}, {'value': '-1.626', 'spread': '1.6493', 'groupId': 'OG001'}]}]}, {'title': 'Day 10', 'categories': [{'measurements': [{'value': '-4.445', 'spread': '1.5779', 'groupId': 'OG000'}, {'value': '-2.784', 'spread': '1.8207', 'groupId': 'OG001'}]}]}, {'title': 'Day 15', 'categories': [{'measurements': [{'value': '-6.110', 'spread': '2.6486', 'groupId': 'OG000'}, {'value': '-4.900', 'spread': '1.7815', 'groupId': 'OG001'}]}]}, {'title': 'Day 28', 'categories': [{'measurements': [{'value': '-6.110', 'spread': '2.6486', 'groupId': 'OG000'}, {'value': '-4.900', 'spread': '1.7815', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (within 1 hour post start of study intervention on Day 1) and Days 3, 5, 10, 15, and 28', 'description': 'Undetectable viral load was considered to be 0 copies/mL for this analysis.', 'unitOfMeasure': 'Log10 copies/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT-infected population included all participants randomly assigned to study intervention, who took at least 1 dose of study intervention, and who had confirmed RSV infection.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs) Through Day 35', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received oral doses of placebo from Day 1 to Day 5.'}], 'classes': [{'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From Day 1 of study intervention up to 28-30 days after last dose of study drug (up to Day 35)', 'description': 'An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An adverse event was considered a TEAE if the event started on or after the study intervention start date (Day 1).', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set (SAS) included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Treatment Emergent Serious Adverse Events (TESAE) Through Day 35', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received oral doses of placebo from Day 1 to Day 5.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From Day 1 of study intervention up to 28-30 days after last dose of study drug (up to Day 35)', 'description': 'An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the criteria listed below: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic and other important medical event.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'SAS included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention.'}, {'type': 'SECONDARY', 'title': 'Plasma Concentrations of Sisunatovir at Days 3 and 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.'}], 'classes': [{'title': 'Day 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '98.26', 'spread': '141.41', 'groupId': 'OG000'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '173.1', 'spread': '231.83', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Anytime between 3 to 8 hours post dose on Day 3, and pre-dose on Day 5', 'unitOfMeasure': 'Nanogram per milliliter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Pharmacokinetic (PK) concentration analysis set included all participants who received at least 1 dose of sisunatovir and in whom at least 1 concentration value was reported. Here, "Number Analyzed" signifies participants evaluable for the specified rows.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.'}, {'id': 'FG001', 'title': 'Placebo', 'description': 'Participants received oral doses of placebo from Day 1 to Day 5.'}], 'periods': [{'title': 'Treatment Phase', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '8'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '8'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}, {'title': 'Follow up Phase', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '8'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '7'}, {'groupId': 'FG001', 'numSubjects': '8'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}], 'recruitmentDetails': 'A total of 16 participants were enrolled at 16 centers in the United States, China, Japan and India.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '16', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Sisunatovir', 'description': 'Participants received oral doses of sisunatovir from Day 1 to Day 5.'}, {'id': 'BG001', 'title': 'Placebo', 'description': 'Participants received oral doses of placebo from Day 1 to Day 5.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '63.9', 'spread': '10.96', 'groupId': 'BG000'}, {'value': '60.8', 'spread': '9.13', 'groupId': 'BG001'}, {'value': '62.3', 'spread': '9.88', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '12', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2024-04-30', 'size': 18487548, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2025-07-29T09:44', 'hasProtocol': True}, {'date': '2024-11-08', 'size': 3032927, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2025-07-29T09:44', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2', 'PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR'], 'maskingDescription': "Participants will be assigned to receive study intervention according to the assigned treatment group from the randomization scheme. Investigators will remain blinded to each participant's assigned study intervention until all participants complete treatment."}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'This is a Phase 2/ Phase 3, superiority, adaptive, two parallel-arm, randomized, multi-center, placebo-controlled, double-blind study.'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 16}}, 'statusModule': {'whyStopped': "Study discontinued due to business reasons. There were no safety concerns in the decision to stop study and no changes to sponsor's assessment of the risk-benefit profile for participants who received sisunatovir in the study.", 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2023-12-08', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-10', 'completionDateStruct': {'date': '2024-09-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-10-27', 'studyFirstSubmitDate': '2023-10-06', 'resultsFirstSubmitDate': '2025-07-29', 'studyFirstSubmitQcDate': '2023-10-06', 'lastUpdatePostDateStruct': {'date': '2025-11-10', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2025-10-27', 'studyFirstPostDateStruct': {'date': '2023-10-12', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2025-11-10', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2024-09-30', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Participants With Respiratory Syncytial Virus (RSV) Related Hospitalization or Death From Any Cause Through Day 28', 'timeFrame': 'From Day 1 (start of study intervention) up to Day 28', 'description': 'RSV related hospitalization included a specialized acute medical care unit within an assisted living facility or nursing home.'}], 'secondaryOutcomes': [{'measure': 'Number of Participants With RSV-Related Visits (Urgent Care/ Emergency Department (ED)/Hospital) or Death From Any Cause Through Day 28', 'timeFrame': 'From Day 1 (start of study intervention) up to Day 28', 'description': 'Participants with RSV related visits in a hospital/urgent care or ED requiring no minimum duration of hospitalization were reported in this outcome measure. Investigators determined if a medical visit was related to RSV. RSV-related medical visits were those attendances that would not otherwise occur in the absence of the RSV infection. These may have included: deterioration or decompensation of the lung function that required supplemental oxygen; development of secondary respiratory tract infections that required antibiotic treatment; management of severe symptoms associated with RSV such as fever; worsening or decompensation of cardiac or renal function in participants with underlying cardiac or renal disease.'}, {'measure': 'Number of Participants With Progression of Lower Respiratory Tract Infection (LRTI) Through Day 10', 'timeFrame': 'From randomization on Day 1 up to Day 10', 'description': 'Progression of LRTI was defined as development of LRTI or transition from non-severe LRTI-RSV at randomization to severe LRTI-RSV at any time up to and including Day 10. LRTI was defined as: \\>= 2 lower respiratory signs or symptoms for at least 24 hours including at least 1 lower respiratory sign; or 3 lower respiratory symptoms for at least 24 hours. Lower respiratory symptoms included following: new or increased sputum, new or increased cough, new or increased dyspnea (shortness of breath). Lower respiratory signs included: new or increased wheezing, new or increased crackles/ronchi based on chest auscultation, respiratory rate \\>= 20 respirations/minute, low or decreased oxygen saturation (O2 less than (\\<) 95 percent (%) or \\<= 90% if pre-season baseline is \\< 95%), need for new or increased oxygen supplementation.'}, {'measure': 'Number of Participants With Development of LRTI Through Day 10', 'timeFrame': 'From randomization on Day 1 up to Day 10', 'description': 'Development of LRTI was defined as transitioning from not having LRTI at randomization but having nsLRTI-RSV or sLRTI-RSV at any time up to and including Day 10. LRTI was defined as: \\>= 2 lower respiratory signs or symptoms for at least 24 hours including at least 1 lower respiratory sign; or 3 lower respiratory symptoms for at least 24 hours. Lower respiratory symptoms included following: new or increased sputum, new or increased cough, new or increased dyspnea (shortness of breath). Lower respiratory signs included: new or increased wheezing, new or increased crackles/ronchi based on chest auscultation, respiratory rate \\>= 20 respirations/minute, low or decreased oxygen saturation (O2 \\< 95 % or \\<= 90% if pre-season baseline is \\< 95%), need for new or increased oxygen supplementation.'}, {'measure': 'Number of Participants With Resolution of LRTI at Day 15', 'timeFrame': 'Day 15', 'description': 'Resolution of LRTI was defined as transition from RSV-related non-severe LRTI (nsLRTI-RSV) or RSV-related severe LRTI (sLRTI-RSV) at randomization to not having nsLRTI and sLRTI-RSV. LRTI was defined as: \\>= 2 lower respiratory signs or symptoms for at least 24 hours including at least 1 lower respiratory sign; or 3 lower respiratory symptoms for at least 24 hours. Lower respiratory symptoms included following: new or increased sputum, new or increased cough, new or increased dyspnea (shortness of breath). Lower respiratory signs included: new or increased wheezing, new or increased crackles/ronchi based on chest auscultation, respiratory rate \\>= 20 respirations/minute, low or decreased oxygen saturation (O2 \\< 95 % or \\<= 90% if pre-season baseline is \\< 95%), need for new or increased oxygen supplementation.'}, {'measure': 'Mean Number of Hospital Free Days Through Day 28', 'timeFrame': 'From Day 1 (start of study intervention) up to Day 28'}, {'measure': 'Number of Participants With Progression of LRTI Through Days 3, 5, 15 and 28', 'timeFrame': 'From randomization on Day 1 up to Days 3, 5, 15 and 28', 'description': 'Progression of LRTI was defined as development of LRTI or transition from non severe LRTI-RSV at randomization to severe LRTI-RSV at any time up to and including Days 3, 5, 15 and 28. LRTI was defined as: \\>= 2 lower respiratory signs or symptoms for at least 24 hours including at least 1 lower respiratory sign; or 3 lower respiratory symptoms for at least 24 hours. Lower respiratory symptoms included following: new or increased sputum, new or increased cough, new or increased dyspnea (shortness of breath). Lower respiratory signs included: new or increased wheezing, new or increased crackles/ronchi based on chest auscultation, respiratory rate \\>= 20 respirations/minute, low or decreased oxygen saturation (O2 \\< 95 % or \\<= 90% if pre-season baseline is \\< 95%), need for new or increased oxygen supplementation.'}, {'measure': 'Number of Participants With Development of LRTI Through Days 3, 5, 15 and 28', 'timeFrame': 'From randomization on Day 1 up to Days 3, 5, 15 and 28', 'description': 'Development of LRTI was defined as transitioning from not having LRTI at randomization but having nsLRTI-RSV or sLRTI-RSV at any time up to and including Days 3, 5, 15 and 28. LRTI was defined as: \\>= 2 lower respiratory signs or symptoms for at least 24 hours including at least 1 lower respiratory sign; or 3 lower respiratory symptoms for at least 24 hours. Lower respiratory symptoms included following: new or increased sputum, new or increased cough, new or increased dyspnea (shortness of breath). Lower respiratory signs included: new or increased wheezing, new or increased crackles/ronchi based on chest auscultation, respiratory rate \\>= 20 respirations/minute, low or decreased oxygen saturation (O2 \\< 95 % or \\<= 90% if pre-season baseline is \\< 95%), need for new or increased oxygen supplementation.'}, {'measure': 'Number of Participants With Resolution of LRTI at Days 3, 5, 10 and 28', 'timeFrame': 'At Days 3, 5, 10 and 28', 'description': 'Resolution of LRTI was defined as transition from nsLRTI-RSV or sLRTI-RSV at randomization to not having nsLRTI and sLRTI-RSV. LRTI was defined as \\>= 2 lower respiratory signs or symptoms for at least 24 hours including at least 1 lower respiratory sign; or 3 lower respiratory symptoms for at least 24 hours. Lower respiratory symptoms included following: new or increased sputum, new or increased cough, new or increased dyspnea (shortness of breath). Lower respiratory signs included: new or increased wheezing, new or increased crackles/ronchi based on chest auscultation, respiratory rate \\>= 20 respirations/minute, low or decreased oxygen saturation (O2 \\< 95% or \\<= 90% if pre-season baseline is \\< 95%), need for new or increased oxygen supplementation.'}, {'measure': 'Number of Participants With Improvement of LRTI at Days 3, 5, 10, 15 and 28', 'timeFrame': 'At Days 3, 5, 10, 15 and 28', 'description': 'Improvement in LRTI status was defined as LRTI resolution or transition from sLRTI-RSV at randomization to nsLRTI-RSV. LRTI was defined as: \\>= 2 lower respiratory signs or symptoms for at least 24 hours including at least 1 lower respiratory sign; or 3 lower respiratory symptoms for at least 24 hours. Lower respiratory symptoms included following: new or increased sputum, new or increased cough, new or increased dyspnea (shortness of breath). Lower respiratory signs included: new or increased wheezing, new or increased crackles/ronchi based on chest auscultation, respiratory rate \\>= 20 respirations/minute, low or decreased oxygen saturation (O2 \\< 95 % or \\<= 90% if pre-season baseline is \\< 95%), need for new or increased oxygen supplementation.'}, {'measure': 'Mean Number of RSV Related Days in Hospital Through Day 28', 'timeFrame': 'From Day 1 (start of study intervention) up to Day 28', 'description': 'RSV related hospitalization included a specialized acute medical care unit within an assisted living facility or nursing home.'}, {'measure': 'Mean Number of RSV Related Days in Intensive Care Unit (ICU) Through Day 28', 'timeFrame': 'From Day 1 (start of study intervention) up to Day 28'}, {'measure': 'Number of Participants With a Clinical Response of Improvement or Resolution at Days 5, 10, 15, and 28', 'timeFrame': 'At Days 5, 10, 15, and 28', 'description': 'Improvement was defined as no new acute respiratory infection (ARI) signs or symptoms, and no worsening of existing signs or symptoms compared to the Day 1 visit. At least one sign or symptom (but not all) present at Day 1 was absent, improved or returned to pre-infection status. Resolution was defined as all ARI signs or symptoms were absent or returned to pre-infection status. Clinical response was evaluated by the investigator.'}, {'measure': 'Number of Participants With Undetectable RSV Viral Load at Days 3, 5, 10, 15 and 28', 'timeFrame': 'At Days 3, 5, 10, 15, and 28', 'description': 'Undetectable RSV viral load at a visit was defined as a central PCR laboratory result of target not detected (TND).'}, {'measure': 'Change From Baseline in Log10 Transformed Total RSV Viral Load at Days 3, 5, 10, 15 and 28', 'timeFrame': 'Baseline (within 1 hour post start of study intervention on Day 1) and Days 3, 5, 10, 15, and 28', 'description': 'Undetectable viral load was considered to be 0 copies/mL for this analysis.'}, {'measure': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs) Through Day 35', 'timeFrame': 'From Day 1 of study intervention up to 28-30 days after last dose of study drug (up to Day 35)', 'description': 'An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An adverse event was considered a TEAE if the event started on or after the study intervention start date (Day 1).'}, {'measure': 'Number of Participants With Treatment Emergent Serious Adverse Events (TESAE) Through Day 35', 'timeFrame': 'From Day 1 of study intervention up to 28-30 days after last dose of study drug (up to Day 35)', 'description': 'An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the criteria listed below: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic and other important medical event.'}, {'measure': 'Plasma Concentrations of Sisunatovir at Days 3 and 5', 'timeFrame': 'Anytime between 3 to 8 hours post dose on Day 3, and pre-dose on Day 5'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Respiratory Syncytial Virus Infection']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://pmiform.com/clinical-trial-info-request?StudyID=C5241007', 'label': 'To obtain contact information for a study center near you, click here.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to learn about the safety and effects of sisunatovir. Sisunatovir is studied for the possible treatment of Respiratory Syncytial Virus (RSV). RSV is a virus that causes lung infections with cold-like symptoms, but it can cause severe illness in some people. Sisunatovir is studied in adults:\n\n* who are not admitted to the hospital and\n* who have high chances of having a severe illness from RSV infection.\n\nThis study is seeking participants who:\n\n* Are confirmed to have RSV.\n* Have symptoms of a lung infection.\n* Are 18 years of age or older.\n* Have one or more of the following which increases the chances of RSV illness:\n* A long-term lung disease.\n* heart failure.\n* a condition that weakens the immune system.\n* Are 65 years of age or older and do not have any of the conditions above\n\nHalf of the participants in this study will receive sisunatovir. The other half will receive a placebo for 5 days. Placebo looks same like the study medicine but does not have any medication. Both sisunatovir and placebo will be taken by mouth. The study will compare the experiences of people receiving sisunatovir to those of the people who do not. This will help decide if sisunatovir is safe and effective.\n\nParticipants will attend about 8-10 study visits over 5 weeks. During this time, they will have:\n\n* visits at the study clinic,\n* blood work,\n* swabs of the nose,\n* questionnaires,\n* a follow-up phone call.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Participants aged 18 years or older at screening.\n* Diagnosis of RSV infection collected within 5 days prior to randomization.\n* New onset or worsening (if present chronically) of at least one of the following signs and/or symptoms consistent with a viral acute respiratory infection (ARI), within 5 days prior to randomization: nasal congestion, nasal discharge, sore throat, cough, sputum production, shortness of breath, or wheezing.\n* Has at least 1 of the following characteristics or underlying medical conditions: a) 65 years of age or older b) Chronic lung disease, c) Heart failure, d) Immunosuppressive disease/condition or immune-weakening medications\n\nExclusion Criteria:\n\n* Any medical or psychiatric condition that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study or interfere with the evaluation of response to the study intervention.\n* Diagnosis of viral respiratory infections other than RSV including influenza and SARS-CoV-2\n* Current need for hospitalization or anticipated need for hospitalization for any reason to provide inpatient/acute care within 24 hours after randomization\n* Any clinically significant ECG abnormality in the pre-dose ECG that, per investigator judgement, may affect participant safety\n* Has hypersensitivity to or other contraindication to any of the components of the study interventions, as determined by the investigator."}, 'identificationModule': {'nctId': 'NCT06079320', 'briefTitle': 'A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection', 'organization': {'class': 'INDUSTRY', 'fullName': 'Pfizer'}, 'officialTitle': 'AN INTERVENTIONAL PHASE 2/3, ADAPTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS', 'orgStudyIdInfo': {'id': 'C5241007'}, 'secondaryIdInfos': [{'id': '2023-505922-32-00', 'type': 'REGISTRY', 'domain': 'CTIS (EU)'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Sisunatovir', 'interventionNames': ['Drug: Sisunatovir']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'Sisunatovir', 'type': 'DRUG', 'description': 'Participants will receive tablets from Day 1 to Day 5', 'armGroupLabels': ['Sisunatovir']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Participants will receive matching placebo tablets from Day 1 to Day 5', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '92844', 'city': 'Garden Grove', 'state': 'California', 'country': 'United States', 'facility': 'National Institute of Clinical Research', 'geoPoint': {'lat': 33.77391, 'lon': -117.94145}}, {'zip': '92683', 'city': 'Westminster', 'state': 'California', 'country': 'United States', 'facility': 'National Institute of Clinical Research', 'geoPoint': {'lat': 33.75918, 'lon': -118.00673}}, {'zip': '33184', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'De La Cruz Research Center, LLC', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '32757', 'city': 'Mt. Dora', 'state': 'Florida', 'country': 'United States', 'facility': 'Adult Medicine of Lake County, Inc.', 'geoPoint': {'lat': 28.80249, 'lon': -81.64452}}, {'zip': '32757', 'city': 'Mt. Dora', 'state': 'Florida', 'country': 'United States', 'facility': 'Adult Medicine of Lake County', 'geoPoint': {'lat': 28.80249, 'lon': -81.64452}}, {'zip': '60453', 'city': 'Oak Lawn', 'state': 'Illinois', 'country': 'United States', 'facility': 'Accellacare - DuPage', 'geoPoint': {'lat': 41.71087, 'lon': -87.75811}}, {'zip': '59701', 'city': 'Butte', 'state': 'Montana', 'country': 'United States', 'facility': 'Mercury Street Medical Group, PLLC', 'geoPoint': {'lat': 46.00382, 'lon': -112.53474}}, {'zip': '11220', 'city': 'Brooklyn', 'state': 'New York', 'country': 'United States', 'facility': 'DM Clinical Research - AOM', 'geoPoint': {'lat': 40.6501, 'lon': -73.94958}}, {'zip': '10455', 'city': 'The Bronx', 'state': 'New York', 'country': 'United States', 'facility': 'CHEAR Center LLC', 'geoPoint': {'lat': 40.84985, 'lon': -73.86641}}, {'zip': '15236', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '75230', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Zenos Clinical Research', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '77043', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Biopharma Informatic, LLC', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '75149', 'city': 'Mesquite', 'state': 'Texas', 'country': 'United States', 'facility': 'Salma Mazhar, MD PA', 'geoPoint': {'lat': 32.7668, 'lon': -96.59916}}, {'zip': '75149', 'city': 'Mesquite', 'state': 'Texas', 'country': 'United States', 'facility': 'SMS Clinical Research', 'geoPoint': {'lat': 32.7668, 'lon': -96.59916}}, {'zip': '201100', 'city': 'Shanghai', 'country': 'China', 'facility': 'Shanghai Minhang District Central Hospital', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'zip': '302039', 'city': 'Jaipur', 'state': 'Rajasthan', 'country': 'India', 'facility': 'Maharaja Agrasen Superspeciality Hospital', 'geoPoint': {'lat': 26.91962, 'lon': 75.78781}}, {'zip': '210-0852', 'city': 'Kawasaki-Shi', 'state': 'Kanagawa', 'country': 'Japan', 'facility': 'Koukankai Koukan Clinic'}, {'zip': '610-0113', 'city': 'Jōyō', 'state': 'Kyoto', 'country': 'Japan', 'facility': 'National Hospital Organization Minami Kyoto Hospital', 'geoPoint': {'lat': 34.84396, 'lon': 135.80561}}, {'zip': '901-0493', 'city': 'Shimajiri', 'state': 'Okinawa', 'country': 'Japan', 'facility': 'Nanbu Tokushukai Hospital', 'geoPoint': {'lat': 27.01665, 'lon': 127.94235}}], 'overallOfficials': [{'name': 'Pfizer CT.gov Call Center', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Pfizer'}]}, 'ipdSharingStatementModule': {'url': 'https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests', 'ipdSharing': 'YES', 'description': "Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\\_trials/trial\\_data\\_and\\_results/data\\_requests."}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Pfizer', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}